Emmaus Life Sciences, Inc. (EMMA)
| Previous close | 0.1000 |
| Open | 0.1015 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1300 |
| Day's range | 0.1015 - 0.1015 |
| 52-week range | 0.0510 - 0.3300 |
| Volume | |
| Avg. volume | 9,559 |
| Market cap | 5.447M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEmmaus Life Sciences Reports Delayed Filing of Annual Report
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.
- PR Newswire
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder). This approval marks a significant milestone in Emmaus' mission to improve the lives of people with SCD around the world and provides access to this important therapy for the patients living with SCD in Puerto Rico. In addition, Endari® is approved in the United State
- PR Newswire
Emmaus Life Sciences Reports Q3 2023 Financial Results
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
